AU2015266854B2 - Improved peptide pharmaceuticals for insulin resistance - Google Patents

Improved peptide pharmaceuticals for insulin resistance Download PDF

Info

Publication number
AU2015266854B2
AU2015266854B2 AU2015266854A AU2015266854A AU2015266854B2 AU 2015266854 B2 AU2015266854 B2 AU 2015266854B2 AU 2015266854 A AU2015266854 A AU 2015266854A AU 2015266854 A AU2015266854 A AU 2015266854A AU 2015266854 B2 AU2015266854 B2 AU 2015266854B2
Authority
AU
Australia
Prior art keywords
lys
omega
seq
asp9
hisi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015266854A
Other languages
English (en)
Other versions
AU2015266854A1 (en
AU2015266854A2 (en
Inventor
John J. Nestor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDERIS DIABETES LLC
Original Assignee
MEDERIS DIABETES LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDERIS DIABETES LLC filed Critical MEDERIS DIABETES LLC
Publication of AU2015266854A1 publication Critical patent/AU2015266854A1/en
Publication of AU2015266854A2 publication Critical patent/AU2015266854A2/en
Application granted granted Critical
Publication of AU2015266854B2 publication Critical patent/AU2015266854B2/en
Priority to AU2020203609A priority Critical patent/AU2020203609B2/en
Priority to AU2023200659A priority patent/AU2023200659A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015266854A 2014-05-28 2015-05-28 Improved peptide pharmaceuticals for insulin resistance Active AU2015266854B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020203609A AU2020203609B2 (en) 2014-05-28 2020-06-02 Improved peptide pharmaceuticals for insulin resistance
AU2023200659A AU2023200659A1 (en) 2014-05-28 2023-02-08 Improved peptide pharmaceuticals for insulin resistance

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004156P 2014-05-28 2014-05-28
US62/004,156 2014-05-28
PCT/US2015/033042 WO2015184177A1 (en) 2014-05-28 2015-05-28 Improved peptide pharmaceuticals for insulin resistance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203609A Division AU2020203609B2 (en) 2014-05-28 2020-06-02 Improved peptide pharmaceuticals for insulin resistance

Publications (3)

Publication Number Publication Date
AU2015266854A1 AU2015266854A1 (en) 2016-12-15
AU2015266854A2 AU2015266854A2 (en) 2017-03-09
AU2015266854B2 true AU2015266854B2 (en) 2020-03-26

Family

ID=54699825

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015266854A Active AU2015266854B2 (en) 2014-05-28 2015-05-28 Improved peptide pharmaceuticals for insulin resistance
AU2020203609A Active AU2020203609B2 (en) 2014-05-28 2020-06-02 Improved peptide pharmaceuticals for insulin resistance
AU2023200659A Pending AU2023200659A1 (en) 2014-05-28 2023-02-08 Improved peptide pharmaceuticals for insulin resistance

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020203609A Active AU2020203609B2 (en) 2014-05-28 2020-06-02 Improved peptide pharmaceuticals for insulin resistance
AU2023200659A Pending AU2023200659A1 (en) 2014-05-28 2023-02-08 Improved peptide pharmaceuticals for insulin resistance

Country Status (18)

Country Link
US (5) US9856306B2 (OSRAM)
EP (2) EP4397374A3 (OSRAM)
JP (4) JP6697807B2 (OSRAM)
KR (3) KR20230084337A (OSRAM)
CN (5) CN106661097A (OSRAM)
AU (3) AU2015266854B2 (OSRAM)
BR (1) BR112016027595B1 (OSRAM)
CA (1) CA2949701C (OSRAM)
DK (1) DK3155017T3 (OSRAM)
ES (1) ES2985732T3 (OSRAM)
FI (1) FI3155017T3 (OSRAM)
HU (1) HUE066179T2 (OSRAM)
IL (3) IL285613B2 (OSRAM)
MX (2) MX384236B (OSRAM)
NZ (2) NZ726623A (OSRAM)
PL (1) PL3155017T3 (OSRAM)
PT (1) PT3155017T (OSRAM)
WO (1) WO2015184177A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
US12257229B2 (en) 2018-01-03 2025-03-25 Spitfire Pharma Llc Peptide pharmaceuticals for treatment of NASH and other disorders

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158962A2 (en) 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
KR20240110072A (ko) 2011-05-18 2024-07-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
WO2014081864A1 (en) * 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
JP6525456B2 (ja) * 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
US9856306B2 (en) 2014-05-28 2018-01-02 Spitfire Pharma, Inc. Peptide pharmaceuticals for insulin resistance
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2019018350A1 (en) 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
KR20220143923A (ko) * 2020-02-21 2022-10-25 스핏파이어 파마, 엘엘씨 Glp-1r 및 gcgr 효능제, 제형 및 사용 방법
WO2022125598A1 (en) * 2020-12-07 2022-06-16 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists
CN113461747B (zh) * 2021-07-12 2023-02-03 吉林化工学院 刺玫果中2个具有降血糖活性的化合物
WO2024239961A1 (zh) * 2023-05-24 2024-11-28 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158965A2 (en) * 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
WO2014081864A1 (en) * 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (ja) 1997-08-15 1999-03-02 Asahi Glass Co Ltd オピオイド様ペプチド
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (ru) 2000-09-20 2002-04-27 Калюжин Олег Витальевич Производные мурамовой кислоты
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
ITRM20040607A1 (it) 2004-12-15 2005-03-15 Biogen S R L Analoghi della dermorfina ad attivita' analgesica.
US7776819B2 (en) 2005-03-03 2010-08-17 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
EP1883419A4 (en) * 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
WO2007002465A2 (en) 2005-06-23 2007-01-04 Rapid Pharmaceuticals, Llc Stabilizing alkylglycoside compositions and methods thereof
EP2045265B1 (en) 2005-09-22 2012-11-21 Biocompatibles Uk Ltd. GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101453037B1 (ko) 2011-03-23 2014-10-21 주식회사 엘지화학 전극조립체 및 이의 제조방법
WO2012158962A2 (en) * 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9856306B2 (en) 2014-05-28 2018-01-02 Spitfire Pharma, Inc. Peptide pharmaceuticals for insulin resistance
CA3093383A1 (en) * 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
EP3735295B1 (en) * 2018-01-03 2024-08-21 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158965A2 (en) * 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
WO2014081864A1 (en) * 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257229B2 (en) 2018-01-03 2025-03-25 Spitfire Pharma Llc Peptide pharmaceuticals for treatment of NASH and other disorders
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists

Also Published As

Publication number Publication date
CA2949701C (en) 2023-12-12
WO2015184177A1 (en) 2015-12-03
US20250136656A1 (en) 2025-05-01
ES2985732T3 (es) 2024-11-07
HUE066179T2 (hu) 2024-07-28
AU2023200659A1 (en) 2023-05-11
US20200277351A1 (en) 2020-09-03
US9856306B2 (en) 2018-01-02
AU2020203609A1 (en) 2020-06-25
US20250313604A1 (en) 2025-10-09
KR20250007694A (ko) 2025-01-14
KR102542164B1 (ko) 2023-06-12
JP2020143066A (ja) 2020-09-10
EP4397374A2 (en) 2024-07-10
EP4397374A3 (en) 2024-10-16
FI3155017T3 (fi) 2024-04-17
DK3155017T3 (da) 2024-04-15
CA2949701A1 (en) 2015-12-03
EP3155017B1 (en) 2024-01-10
US20170096468A1 (en) 2017-04-06
BR112016027595A2 (pt) 2017-08-15
AU2015266854A1 (en) 2016-12-15
US20180194826A1 (en) 2018-07-12
US10577405B2 (en) 2020-03-03
AU2020203609B2 (en) 2022-11-17
EP3155017A1 (en) 2017-04-19
IL249044B (en) 2020-07-30
PT3155017T (pt) 2024-05-14
IL275526A (en) 2020-08-31
EP3155017A4 (en) 2019-03-27
BR112016027595A8 (pt) 2021-07-20
IL285613A (en) 2021-09-30
JP6697807B2 (ja) 2020-05-27
MX371033B (es) 2020-01-13
MX384236B (es) 2025-03-14
BR112016027595B1 (pt) 2023-12-26
KR20230084337A (ko) 2023-06-12
CN109865142A (zh) 2019-06-11
KR20170010412A (ko) 2017-01-31
NZ726623A (en) 2020-02-28
JP2017519739A (ja) 2017-07-20
CN117582516A (zh) 2024-02-23
IL275526B (en) 2021-08-31
NZ757113A (en) 2022-08-26
CN106661097A (zh) 2017-05-10
MX2016015594A (es) 2017-03-23
AU2015266854A2 (en) 2017-03-09
JP2022172128A (ja) 2022-11-15
IL249044A0 (en) 2017-01-31
NZ764813A (en) 2024-07-05
PL3155017T4 (pl) 2024-06-17
PL3155017T3 (pl) 2024-06-17
CN117180445A (zh) 2023-12-08
IL285613B1 (en) 2024-07-01
CN113264994A (zh) 2021-08-17
JP2024102119A (ja) 2024-07-30
IL285613B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
US11911447B2 (en) Peptide pharmaceuticals for insulin resistance
US20250313604A1 (en) Peptide pharmaceuticals for insulin resistance
AU2012255119B2 (en) Improved peptide pharmaceuticals for insulin resistance
US20200289653A1 (en) Improved peptide pharmaceuticals for insulin resistance
NZ617824B2 (en) Improved peptide pharmaceuticals for insulin resistance

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 FEB 2017

FGA Letters patent sealed or granted (standard patent)